(Q40662515)

22 September 2017

N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism (English)

1 reference

22 September 2017

S P Spielberg

1

1 reference

22 September 2017

1 October 1996

1 reference

Journal of Pharmacokinetics and Pharmacodynamics

22 September 2017

1 reference

22 September 2017

24

1 reference

22 September 2017

509-519

1 reference

22 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02353477

22 September 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Nomenclature for N-acetyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Molecular mechanism of slow acetylation of drugs and carcinogens in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Diverse point mutations in the human gene for polymorphic N-acetyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

A simple test for acetylator phenotype using caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Clinical consequences of polymorphic acetylation of basic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

In vitro evaluation of a toxic metabolite of sulfadiazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Sulfamethoxazole is metabolized to the hydroxylamine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

An in vitro investigation of predisposition to sulphonamide idiosyncratic toxicity in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Systemic glutathione deficiency in symptom-free HIV-seropositive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Adverse Reactions to Trimethoprim-Sulfamethoxazole in Patients with the Acquired Immunodeficiency Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02353477

Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes

21 January 2018

1 reference

12 December 2020

Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs

1 reference

12 December 2020

Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus

1 reference

12 December 2020

N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans

1 reference

12 December 2020

Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity

1 reference

12 December 2020

N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes

1 reference

12 December 2020

Glutathione transferase mu deficiency is not a marker for predisposition to sulphonamide toxicity

1 reference

12 December 2020

Sulfadiazine-induced allergy in six Doberman pinschers

1 reference

12 December 2020

Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis

1 reference

12 December 2020

Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver

1 reference

12 December 2020

In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity.

1 reference

12 December 2020

Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine

1 reference

12 December 2020

Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides.

1 reference

12 December 2020

Genetic control of isoniazid metabolism in man

1 reference

12 December 2020

Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites

1 reference

12 December 2020

Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity

1 reference

12 December 2020

Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone

1 reference

12 December 2020

Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver

1 reference

12 December 2020

Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides

1 reference

12 December 2020

Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes

1 reference

12 December 2020

Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions

1 reference

12 December 2020

Salmonella typhimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02353477

1 reference

22 September 2017

1 reference

PubMed ID

9131488